Identification and prediction method for gamma-ray radiation damage protection relocation medicine

By analyzing gene expression profile data and calculating the reverse biological effects, potential gamma-ray radiation protection drugs were screened, overcoming the shortcomings of existing drugs and achieving efficient and safe discovery and screening of radiation protection drugs.

CN118969093APending Publication Date: 2024-11-15ACADEMY OF MILITARY MEDICAL SCIENCES

Patent Information

Application Number
CN202411199207.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing gamma-ray radiation protection drugs have limitations such as limited variety, short effective time, significant adverse reactions, unclear targets and mechanisms of action, long development cycles, high costs, and high risks for drugs with novel structures, and a lack of effective radiation protection drugs for emergency response.

Method used

By extracting gene expression profile datasets of target biological effects and candidate repositioning drugs, calculating ES scores, selecting candidate drugs based on the reverse biological effects, and combining large-scale pharmacology databases and in vivo experimental validation, potential radiation protection repositioning drugs were screened out.

Benefits of technology

This reduces the time and economic cost of repositioning drug discovery, improves the success rate, and provides highly safe and bioavailable radiation protection drugs for emergency response to sudden events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118969093A_ABST
    Figure CN118969093A_ABST
Patent Text Reader

Abstract

The invention provides an identification and prediction method for gamma-ray radiation damage protection relocation drugs, and belongs to the technical field of drug relocation, and the method comprises the following steps: extracting a target gene expression profile data set of a target biological effect and a candidate gene expression profile data set of candidate relocation drugs; calculating ES scores of the target gene expression profile data set and the candidate gene expression profile data set; and based on biological effect reversion, selecting a corresponding candidate drug for protecting the target biological effect in the candidate gene expression profile data set according to the ES score. The method not only further reduces the time and economic cost of finding the relocation radiation protection drug, but also improves the success rate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug repositioning, and in particular to a method for identifying and predicting a repositioned drug for protection against gamma-ray radiation damage. Background Art

[0002] Existing research on radiation protection drugs in China mainly focuses on antioxidants, estrogens and sulfhydryls, which have defects such as limited varieties, short effective time, large adverse reactions, unclear targets and mechanisms, and the effect needs to be improved. Many compounds that may have radiation protection effects are still in the experimental stage, and there is a clear gap in drugs for handling and treating nuclear radiation-related emergencies. There is an urgent need to develop a new generation of radiation protection drugs with clear efficacy, clear mechanism and few side effects.

[0003] The development cycle of completely new structural drugs is long, costly, high-risk, and has a low success rate. Exploring new uses and new indications for known drugs, namely drug repositioning, is becoming an important strategy for drug discovery. However, the discovery of most representative repositioned drugs is accidental, not the result of rational design. Due to the large number of diseases and known drugs, it is too costly to screen new uses of known drugs through experiments. Therefore, identifying and predicting drug repositioning through analytical and computational methods has become a hot topic in computational biology and systems biology research in recent years. Summary of the invention

[0004] The present invention provides a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug, so as to solve the defects of the prior art.

[0005] The present invention provides a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug, comprising: S1: Extract target gene expression profile datasets for target biological effects and candidate gene expression profile datasets for candidate repositioning drugs; S2: Calculating the ES scores of the target gene expression profile dataset and the candidate gene expression profile dataset; S3: Based on the reversibility of the biological effect, candidate drugs for protecting the target biological effect in the candidate gene expression profile dataset are selected according to the ES score.

[0006] According to a method for identifying and predicting repositioned drugs for protection against γ-ray radiation damage provided by the present invention, the target biological effect in step S1 is a γ-ray radiation biological effect.

[0007] According to a method for identifying and predicting a repositioned drug for protecting against γ-ray radiation damage provided by the present invention, the target gene expression profile data set is selected from the GEO database, and the candidate gene expression profile data set is selected from the LINCS database.

[0008] According to a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug provided by the present invention, in step S1, the step of acquiring the candidate gene expression profile data set further comprises: S11: introducing a LINCS database, and selecting a plurality of compounds from the LINCS database; S12: From the LINCS database, the gene expression profiles generated by each selected compound acting on multiple cells at various concentrations are downloaded and analyzed to obtain the cell response expression profile and the control group expression profile; S13: Outputting the cell response expression profile and the control group expression profile as a candidate gene expression profile dataset.

[0009] According to a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug provided by the present invention, step S2 further comprises: S21: performing correlation alignment on the target gene expression profile dataset and the candidate gene expression profile dataset according to cell types to obtain a correlation dataset; S22: converting all gene IDs in the relevant data set into a unified gene symbol to obtain a unified data set; S23: Calculate the ES scores of the candidate repositioned drugs and target biological effects in the unified dataset using R language.

[0010] According to a method for identifying and predicting repositioned drugs for protecting against γ-ray radiation damage provided by the present invention, the unified gene symbols in step S22 are official gene symbols.

[0011] According to a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug provided by the present invention, the value range of the ES score in step S2 is:

[0012] in, The ES score obtained for calculation.

[0013] According to a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug provided by the present invention, the ES score of the candidate drug selected in step S3 has a value range of: .

[0014] According to a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug provided by the present invention, step S3 further comprises: S31: selecting candidate repositioning drugs whose ES scores are less than 0 and whose absolute values ​​of the ES scores meet a preset threshold according to the calculated ES scores, to obtain a plurality of candidate drugs; S32: Taking the intersection of multiple candidate drugs, and selecting the candidate drugs that appear most frequently in multiple cell lines as candidate drugs for protecting the target biological effect.

[0015] According to a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug provided by the present invention, step S3 further includes: S33: Conducting physical and chemical information analysis, pharmacological mechanism analysis and action mechanism analysis on the candidate drug to experimentally verify the candidate drug.

[0016] The present invention provides a method for identifying and predicting repositioned drugs for protecting against gamma-ray radiation damage. The method is based on a large-scale pharmacology database and comprehensively utilizes gene expression spectrum data of radiation response and multiple drug actions to establish a method for rationally and accurately identifying potential repositioned drugs for radiation protection by means of computational biology and systems biology. The method is combined with in vivo experiments for verification, laying a foundation for building a technical system for screening and evaluating radiation protection drugs. The method not only further reduces the time and economic cost of repositioned drug discovery, but also improves the success rate, allowing the research and development of radiation damage protection drugs to enter a stage of combining rational design and experimental screening. In addition, the potential radiation protection repositioned drugs proposed by the method of the present invention have guaranteed safety and bioavailability, are easy to obtain and use, and are more suitable for emergency disposal and treatment of related emergencies. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 A schematic flow chart of a method for identifying and predicting a repositioned drug for protection against gamma-ray radiation damage provided by an embodiment of the present invention; Figure 2 A schematic diagram of the steps for obtaining a candidate gene expression profile dataset provided in an embodiment of the present invention; Figure 3 A schematic diagram of a method for calculating ES scores for a target gene expression profile dataset and a candidate gene expression profile dataset provided in an embodiment of the present invention; Figure 4 A schematic diagram of a method for selecting a candidate drug according to an embodiment of the present invention; Figure 5 A schematic diagram of improving the survival rate of experimental mice after irradiation with a 9 Gy dose of gamma rays by intraperitoneal injection of lenalidomide and losartan according to an embodiment of the present invention; Figure 6A schematic diagram of the effect of intraperitoneal injection of lenalidomide and losartan on the body weight changes of experimental mice after irradiation with a 9 Gy dose of gamma rays provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0019] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings in the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments, and they should not be understood as limitations on the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. In the description of the present invention, it should be understood that the terms used are only for descriptive purposes and cannot be understood as indicating or implying relative importance.

[0020] like Figure 1 As shown, the present invention provides a method for identifying and predicting a gamma-ray radiation damage protection repositioning drug, comprising: S1: Extract target gene expression profile datasets for target biological effects and candidate gene expression profile datasets for candidate repositioning drugs.

[0021] Wherein, the target biological effect in step S1 is the biological effect of gamma-ray radiation.

[0022] This embodiment takes the prediction of potential gamma-ray radiation damage protection repositioning drugs based on the reverse property of biological effects as an example, so the target biological effect in step S1 is the gamma-ray radiation biological effect.

[0023] The target gene expression profile dataset is selected from the GEO database, and the candidate gene expression profile dataset is selected from the LINCS database.

[0024] The gene expression profile dataset used to represent the biological effects of γ-ray radiation is the collection with ID GSE44245 in Gene Expression Omnibus (GEO), and the candidate repositioning drug gene expression profiles are from the Library of integrated network-based cellular signatures (LINCS) database.

[0025] like Figure 2 As shown, in step S1, the step of acquiring the candidate gene expression profile dataset further includes: S11: introducing a LINCS database, and selecting a plurality of compounds from the LINCS database; S12: From the LINCS database, the gene expression profiles generated by each selected compound acting on multiple cells at various concentrations are downloaded and analyzed to obtain the cell response expression profile and the control group expression profile; S13: Outputting the cell response expression profile and the control group expression profile as a candidate gene expression profile dataset.

[0026] In steps S11 to S13, 4617 compounds in LINCS were first identified through manual screening, and then 55129 response expression spectra obtained at different time points after these compounds were applied to various cells at different concentrations, as well as 4388 expression spectra of control group cells, were extracted and integrated. These compounds provided materials and objects for the subsequent prediction of γ-ray radiation protection repositioning drugs.

[0027] S2: Calculate the ES scores of the target gene expression profile dataset and the candidate gene expression profile dataset.

[0028] like Figure 3 As shown, step S2 further includes: S21: performing correlation alignment on the target gene expression profile dataset and the candidate gene expression profile dataset according to cell types to obtain a correlation dataset; S22: converting all gene IDs in the relevant data set into a unified gene symbol to obtain a unified data set; Wherein, the unified gene symbol in step S22 is the official gene symbols.

[0029] In steps S21 to S22, we first compare the cell lines involved in the gene expression profiles in the GSE44245 and LINCS collections, align them according to the cell types, and select the gene expression profiles of the four most relevant cell lines in LINCS that act on drugs for subsequent analysis. Then, we perform gene ID conversion and convert the gene IDs in the GSE44245 and LINCS collections into official gene symbols to facilitate subsequent comparison.

[0030] S23: Calculate the ES scores of the candidate repositioned drugs and target biological effects in the unified dataset using R language.

[0031] In step S23, the data is processed with the help of R language, and the whole genome expression is analyzed according to the cellular response data of the two input sets, and ES is calculated based on this. The R language is a programming language used for statistical analysis and graphical representation, and can perform data analysis through statistical calculations, data operations, etc.

[0032] The value range of the ES score in step S2 is:

[0033] in, The ES score obtained for calculation.

[0034] Enrichment scores (ES) are used to characterize and measure the similarity of the biological effects of cells responding to γ-ray radiation and responding to different disturbances. They are between 1 and -1. A value greater than 0 indicates that the biological effect caused by the drug is similar to that of γ-ray radiation, whereas a value less than 0 indicates that the biological effect is opposite. The absolute value represents the degree of similarity or oppositeness.

[0035] S3: Based on the reversibility of the biological effect, candidate drugs for protecting the target biological effect in the candidate gene expression profile dataset are selected according to the ES score.

[0036] The ES score of the candidate drug selected in step S3 has a value range of: .

[0037] From step S1, this embodiment predicts potential repositioned drugs for protection against γ-ray radiation damage based on the reverse property of biological effects. Therefore, when the target biological effect is selected as the γ-ray radiation biological effect, in order to obtain repositioned drugs that can protect against γ-ray radiation damage, it is necessary to select drugs with an ES score less than 0.

[0038] like Figure 4 As shown, step S3 further includes: S31: selecting candidate repositioning drugs whose ES scores are less than 0 and whose absolute values ​​of the ES scores meet a preset threshold according to the calculated ES scores, to obtain a plurality of candidate drugs; S32: Taking the intersection of multiple candidate drugs, and selecting the candidate drugs that appear most frequently in multiple cell lines as candidate drugs for protecting the target biological effect.

[0039] For the calculation results of multiple cell lines, only the drugs approved by the FDA are considered. The result of ES < 0 indicates that the biological effect of the corresponding drug on cells is opposite to that of γ-ray radiation, and they may become candidate drugs for radiation protection. The threshold is selected to obtain the possible radiation protection drugs in multiple cell lines, and the intersection is taken. The compounds that appear in multiple cell lines are given priority as candidate drugs.

[0040] Wherein, step S3 also includes: S33: Conducting physical and chemical information analysis, pharmacological mechanism analysis and action mechanism analysis on the candidate drug to experimentally verify the candidate drug.

[0041] After obtaining the above-mentioned candidate drugs, it is necessary to investigate the physical and chemical information, pharmacological properties, mechanism of action, etc. of the candidate drugs, as well as their previous applications in the field of radiation response regulation, comprehensively judge and determine the candidate drugs for experimental verification, and review the relevant research on the use of candidate drugs for radiation response regulation reported in published literature to verify the feasibility and effectiveness of the above-mentioned prediction method.

[0042] The following is another example of an identification and prediction method for repositioning drugs for protection against γ-ray radiation damage provided by the present invention.

[0043] First, the data set involved in the present invention is introduced in detail.

[0044] Gene Expression Omnibus (GEO): GEO is a functional database containing a large number of high-throughput gene expression profiles from genome hybridization experiments, including the expression profiles of DNA damage response proteins before and after different types and doses of ionizing radiation measured on a variety of human cell lines. In GEO, the conditions "Series", "Expression profiling by array" and "Homo sapiens" were limited. At the same time, in order to ensure accurate matching with LINCS, the data set with the platform of GPL570 or GPL96 must be selected. Keywords such as "ionizing radiation", "DNA damage response" and "radiosensitivity" were used to search and manually screen the results. Finally, the gene expression profile provided by the GSE44245 data set (https: / / www.ncbi.nlm.nih.gov / geo / query / acc.cgi?acc=GSE44245) was selected to characterize the biological effects of radiation. The "Series Matrix File(s)" file in TXT format can be directly downloaded in the "Download family" table at the bottom of the page. This dataset contains gene expression data obtained by gene expression chip measurement 24 hours after human lymphocytes were irradiated with 5 Gy gamma rays, providing the whole genome changes of the cells under radiation. The platform used is GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0Array, which contains 6 samples in total, 3 of which are non-irradiated control groups (GSM1081193-GSM1081195) and the other 3 are 5 Gy gamma ray irradiation experimental groups (GSM1081196-GSM1081198).

[0045] Library of integrated network-based cellular signatures (LINCS): LINCS is a comprehensive, large-scale database of small molecule drug pharmacology. It contains a large number of gene expression profiles of existing drugs at different concentrations acting on a variety of cell lines, that is, gene expression data of different cells in response to a series of perturbations, including compounds, gene mutations, microenvironments, and diseases, and provides control group and experimental group data for download. This study downloaded the data labeled "LINCS 1000 Chemical Perturbations" and integrated it for subsequent drug prediction.

[0046] Secondly, the reverseness of biological effects is calculated and compared.

[0047] First, cell line alignment and ID conversion were performed. Since the data in GSE44245 were obtained from experiments on human lymphocytes irradiated with gamma rays, the cell lines must be aligned and unified first, and the data on drugs acting on related cell types (human hematopoietic system) in LINCS were screened out. By comparison, it was found that the most relevant cells included in LINCS were multiple leukemia subtype cell lines, so the gene expression profiles on the following four cell lines were selected for subsequent analysis: human leukemia cell line NOMO1, human acute myeloid leukemia cell line PL21, human myelodysplastic syndrome cell line SKM1, and human diffuse large B-cell lymphoma cell line WSUDLCL2. The gene expression profile data obtained from the perturbation experiments of compounds in LINCS acting on the above four cell lines were screened out, and the gene ID conversion of LINCS expression profile data was completed in combination with the GPL96 platform annotation file, and converted into official gene symbols. The gene ID of the gamma-ray irradiation expression profile was also converted into official gene symbols based on the GPL570 platform annotation information.

[0048] Secondly, the enrichment scores (ES) were calculated. Data processing was performed using R language. Based on the cell response expression profiles before and after γ-ray irradiation, different drug groups and control groups, the Limma package was used to analyze the whole genome differential expression of γ-ray irradiation and different drug effects, and the Fold change (FC) was calculated to obtain all differentially expressed genes under irradiation and all drug effects. Using the Gene Set Enrichment Analysis (GSEA) method, the ES of various drugs acting on different cell lines compared with the radiation response were calculated based on FC matching. This score represents the similarity of the biological effects between the two.

[0049] The subsequent work will be to identify candidate repositioned radiation protection drugs to be verified.

[0050] Only FDA-approved drugs were considered for screening candidate drugs to be verified. For the prediction results of the four leukemia subtype cell lines, they were sorted from small to large according to ES, and the entries with ES < 0 were retained. The threshold was determined to be -0.25. The drugs that met the threshold criteria in the four cell lines were extracted and listed, as shown in Table 1, with a total of 29 entries and 19 compounds. The appearance of each drug in the lists of several cell lines was counted, and the drugs that appeared in multiple cell lines at the same time were paid attention to. It can be seen that a total of 7 drugs appeared in more than 2 (including 2) cell lines, namely: menadione, losartan, lenalidomide, rosiglitazone, pimozide, nimodipine and fluspirilene.

[0051] Table 1. Compounds with enrichment score (ES) < -0.25 in reverse biological effect comparison that may become γ-ray radiation protection repositioning drugs

[0052] In Table 1, Drugbank ID is the number of the drug in the DrugBank database, Drug name is the name of the drug in the DrugBank database, Drug group is the group of the drug in the DrugBank database, investigational means that the drug is in the approval stage for at least one indication, approved;investigational and approved;nutraceutical mean that the drug belongs to different categories for different indications, Cell line means the cell line to which the drug belongs, Enrichment score is the ES value of the drug, and Count means the number of times the drug appears in different cell line lists.

[0053] The basic information of these drugs, including chemical structure, molecular weight, original indications, mechanism of action and known targets, was obtained from the DrugBank database. The research progress of these drugs in experiments related to various indications was investigated through published literature, as well as whether there were previous research reports and details on their use in the fields of radiation protection or radiosensitization. Lenalidomide and losartan were focused on. Lenalidomide is an immunomodulatory drug with anti-tumor, anti-angiogenic and anti-inflammatory properties. It was originally used to treat multiple tumors and anemia in low- and intermediate-risk myelodysplastic syndromes. Known targets include CRBN, TNFSF11, CDH5 and PTGS2. Lenalidomide exerts its effects through immunomodulatory effects, such as changing cytokine production (inhibiting the production of proinflammatory cytokines TNF-α, IL-1, etc., and increasing the production of anti-inflammatory cytokines IL-10, etc.), regulating T cell function (promoting CD3T cell proliferation, increasing the production of IL-2 and IFN-γ in T lymphocytes), enhancing NK cell-mediated cytotoxicity, etc., regulating immune responses, and inhibiting NF-κB and MAPK signaling pathways. Losartan is a renin-angiotensin system inhibitor that blocks the binding of angiotensin II to the AT1 receptor and was originally used to treat hypertension and diabetic nephropathy. Known targets include AGTR1 and AT1R. The compound inhibits oxidative stress-mediated cell damage and apoptosis, reduces oxidative stress, and exhibits significant systemic antioxidant potential. It inhibits the TGF-β1 pathway by upregulating PPARγ, while regulating metabolism and Smadsignaling pathways, increasing the expression of Smurf2 and Smurf1, inhibiting the expression of TGF-β1, collagen, and Smad, and reducing Smad2 and Smad3 phosphorylation. Based on the above information, an in vivo experimental verification of the effect of lenalidomide and losartan for γ-ray radiation protection was conducted.

[0054] Finally, potential radiation protection repositioning drug candidates are validated.

[0055] Specifically, in vivo experimental verification: animal experiments were used to verify the protective effect of lenalidomide against γ-ray radiation. Six-week-old male C57BL / 6J mice were selected and divided into 4 groups: control group, simple irradiation group, irradiation + lenalidomide group, irradiation + losartan group, with 9 mice in each group. A single intraperitoneal injection was given 2 hours before irradiation, with lenalidomide concentration of 100 mg / kg and losartan concentration of 80 mg / kg. Using cobalt-60 ( 60 The mice were irradiated with 9 Gy of gamma rays from a Co) radiation source at a dose rate of 66.04 cGy / min. The survival rate of mice in each group was observed and recorded 30 days after irradiation, and the body weight of mice was measured. Figure 5 and Figure 6 As shown, Figure 5 and Figure 6Control is the control group, IR is the irradiation group alone, lenalidomide is the irradiation + lenalidomide (100 mg / kg) group, and losartan is the irradiation + losartan (80 mg / kg) group. It can be obtained that all mice in the irradiation group died on the 13th day after irradiation, and mice in the irradiation + lenalidomide group and the irradiation + losartan group survived until the 30th day after irradiation. From the 11th day after irradiation, the number of surviving mice in the irradiation + lenalidomide group was higher than that in the control group; from the 13th day after irradiation, the number of surviving mice in the irradiation + losartan group was higher than that in the control group; from the weight changes of mice, it can be seen that the average weight of mice in the irradiation + lenalidomide group and the irradiation + losartan group began to increase from the 11th day after irradiation. The above results show that intraperitoneal injection of 100 mg / kg lenalidomide and 80 mg / kg losartan has a certain protective effect against higher doses (9 Gy) of γ-ray irradiation, and further confirm the accuracy and practical significance of this identification and prediction method.

[0056] Due to the wide variety of known compounds, the cost of drug repositioning research completely through experimental screening is still too high. In recent years, with the rapid development of sequencing technology, the accumulation of a large amount of multivariate expression spectrum data has provided an opportunity for the introduction of analytical and computational methods in drug discovery. Based on a large-scale pharmacology database, the present invention comprehensively uses gene expression spectrum data of radiation response and the effects of multiple drugs to establish a method for rationally and accurately identifying potential radiation protection repositioning drugs through computational biology and systems biology approaches. Combined with in vivo experiments for verification, it lays the foundation for the construction of a radiation protection drug screening and evaluation technology system. The process of the present invention combined with experimental technology can further reduce the time and economic cost of repositioning drug discovery, improve the success rate, and enable the research and development of radiation damage protection drugs to enter a stage of combining rational design and experimental screening. The proposed potential radiation protection repositioning drugs lenalidomide and losartan are marketed drugs with guaranteed safety and bioavailability, and are easy to obtain and use.

[0057] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for identifying and predicting a repositioned drug for protection against γ-ray radiation damage, characterized in that: include: S1: Extract target gene expression profile datasets for target biological effects and candidate gene expression profile datasets for candidate repositioning drugs; S2: Calculating the ES scores of the target gene expression profile dataset and the candidate gene expression profile dataset; S3: Based on the reversibility of the biological effect, candidate drugs for protecting the target biological effect in the candidate gene expression profile dataset are selected according to the ES score.

2. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 1, characterized in that: The target biological effect in step S1 is a gamma-ray radiation biological effect.

3. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 1, characterized in that: The target gene expression profile dataset is selected from the GEO database, and the candidate gene expression profile dataset is selected from the LINCS database.

4. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 3, characterized in that: In step S1, the step of acquiring the candidate gene expression profile dataset further includes: S11: introducing a LINCS database, and selecting a plurality of compounds from the LINCS database; S12: From the LINCS database, the gene expression profiles generated by each selected compound acting on multiple cells at various concentrations are downloaded and analyzed to obtain the cell response expression profile and the control group expression profile; S13: Outputting the cell response expression profile and the control group expression profile as a candidate gene expression profile dataset.

5. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 1, characterized in that: Step S2 further comprises: S21: performing correlation alignment on the target gene expression profile dataset and the candidate gene expression profile dataset according to cell types to obtain a correlation dataset; S22: converting all gene IDs in the relevant data set into a unified gene symbol to obtain a unified data set; S23: Calculate the ES scores of the candidate repositioned drugs and target biological effects in the unified dataset using R language.

6. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 5, characterized in that: The unified gene symbols in step S22 are official gene symbols.

7. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 1, characterized in that: The value range of the ES score in step S2 is: in, The ES score obtained for calculation.

8. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 7, characterized in that: The ES score of the candidate drug selected in step S3 has a value range of: .

9. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 8, characterized in that: Step S3 further comprises: S31: selecting candidate repositioning drugs whose ES scores are less than 0 and whose absolute values ​​of the ES scores meet a preset threshold according to the calculated ES scores, to obtain a plurality of candidate drugs; S32: Taking the intersection of multiple candidate drugs, and selecting the candidate drugs that appear most frequently in multiple cell lines as candidate drugs for protecting the target biological effect.

10. The method for identifying and predicting a gamma-ray radiation damage protection repositioning drug according to claim 9, characterized in that: Step S3 also includes: S33: Conducting physical and chemical information analysis, pharmacological mechanism analysis and action mechanism analysis on the candidate drug to experimentally verify the candidate drug.

Citation Information

Patent Citations

  • Method for screening radiation biomarkers and predicting radiation dose based on radiation response biological pathway

    CN110349633A

  • Method for identifying and predicting human genes related to space radiation damage protection drug target

    CN111402954A

  • Artifical turf and method for manufacturing the same

    KR102304524B1

  • Methods for screening and selecting target agents from molecular databases

    US20190010533A1

Cited By

  • Method for identifying and predicting repositioned drug for protection against γ-ray radiation damage

    WO2026046290A1